The latest financial statement is for the quarter ending 2025-06-30.
| Cash Flow | 2025-06-30 |
|---|---|
| Tax incentive receivable | -1,874 |
| Operating lease liabilities | -421 |
| Royalties payable | 1,988 |
| Share-based compensation | 72,291 |
| Net income/(loss) | -4,398 |
| Prepaid expenses | 3,859 |
| Other current liabilities | -2,488 |
| Other current assets | 572 |
| Inventory | 6,301 |
| Income taxes | -9,454 |
| Accrued expenses | 27,106 |
| Accounts receivable | 51,362 |
| Accounts payable | -7,832 |
| Loss on extinguishment of debt | -407 |
| Foreign exchange (gain)/loss | 1,567 |
| Depreciation | 588 |
| Amortization of debt issuance costs | 1,346 |
| Accretion of redemption premium on debt | 0 |
| Accretion of ripsa | 1,654 |
| Net cash provided by/(used in) operating activities | 19,000 |
| Purchases of furniture and equipment | 535 |
| Net cash used in investing activities | -535 |
| Repurchase of ripsa | 109,921 |
| Proceeds from ripsa | 0 |
| Repayment of 2023 term loans | 0 |
| Proceeds from exercise of share options | 10,108 |
| Proceeds from term loans | 122,500 |
| Payments of withholding taxes from share-based awards | 4,287 |
| Payment of debt issuance costs | 0 |
| Net cash provided by financing activities | 18,400 |
| Effect of exchange rate changes on cash and cash equivalents | 1,394 |
| Net change in cash and cash equivalents | 38,259 |
Verona Pharma plc (VRNA)
Verona Pharma plc (VRNA)